Academic literature on the topic 'Sévérité de l'atteinte hépatique'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Sévérité de l'atteinte hépatique.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Journal articles on the topic "Sévérité de l'atteinte hépatique"
Debray, D. "L'atteinte hépatique de la mucoviscidose." Archives de Pédiatrie 19 (May 2012): S23—S26. http://dx.doi.org/10.1016/s0929-693x(12)71104-1.
Full textLecoindre, Alexis. "Comment réaliser une biopsie hépatique afin d’en tirer le maximum d’informations ?" Le Nouveau Praticien Vétérinaire canine & féline 20, no. 83 (May 2023): 6–9. http://dx.doi.org/10.1051/npvcafe/2023020.
Full textSchaub. "Hautveränderungen bei Lebererkrankungen." Praxis 91, no. 23 (June 1, 2002): 1037–41. http://dx.doi.org/10.1024/0369-8394.91.23.1037.
Full textKalo, T., C. Leport, and J. L. Vilde. "L'atteinte hépatique au cours de la rubéole acquise. Etude chez 10 malades." Médecine et Maladies Infectieuses 21, no. 4 (April 1991): 241–43. http://dx.doi.org/10.1016/s0399-077x(05)80166-0.
Full textKetari, S., B. Ben Dhaou, F. Boussema, S. Kochbati, O. Cherif, and L. Rokbanii. "L'atteinte hépatique au cours de la sarcoïdose: à propos de six cas." La Revue de Médecine Interne 28 (June 2007): 148. http://dx.doi.org/10.1016/j.revmed.2007.03.302.
Full textGominon, A. L., E. Frison, J. Vergniol, H. Clouzeau, S. Bui, M. Fayon, V. de Ledinghen, and T. Lamireau. "CO-12 – Évolutivité de l'atteinte hépatique de la mucoviscidose étudiée par élastométrie impulsionnelle." Archives de Pédiatrie 22, no. 5 (May 2015): 213. http://dx.doi.org/10.1016/s0929-693x(15)30115-9.
Full textMoret, Meier, Rotman, Lepori, and Lamy. "Fièvre d'origine indéterminée avec hépatite granulomateuse, uvéite et insuffisance rénale aiguë." Praxis 94, no. 1 (January 1, 2005): 25–30. http://dx.doi.org/10.1024/0369-8394.94.1.25.
Full textLabrune, Ph, M. Fabre, P. Trioche, B. Estournet-Mathiaud, M. C. Grangeponte, C. Rambaud, C. Maurage, M. Odièvre, and O. Bernard. "L'atteinte hépatique du syndrome de jeune: a propos de trois observations illustrant l'efficacité du traitement par l'acide ursodeoxycholique." Archives de Pédiatrie 6 (January 1999): S559. http://dx.doi.org/10.1016/s0929-693x(99)81712-6.
Full textGhannei, O., S. Ben Amor, and M. Trimech. "Le déficit en vitamine D est-il associé à la sévérité de la maladie hépatique chez les patients avec stéatose hépatique non alcoolique (NAFLD) ?" Annales d'Endocrinologie 84, no. 1 (February 2023): 222. http://dx.doi.org/10.1016/j.ando.2022.12.388.
Full textPoujois, A., N. Djebrani-Oussedik, R. Sobesky, N. Tinant, C. Collet, D. Habès, D. Debray, et al. "Cuivre échangeable : un reflet de la sévérité de l’atteinte extra-hépatique dans la maladie de Wilson." Archives de Pédiatrie 23, no. 10 (October 2016): 1080. http://dx.doi.org/10.1016/j.arcped.2016.07.017.
Full textDissertations / Theses on the topic "Sévérité de l'atteinte hépatique"
Zambon, Azevedo Vittoria. "Mise au point d’un nouvel outil diagnostique de l’obésité sarcopénique : relations avec la dysfonction du tissu adipeux, l’insulinorésistance et la sévérité de l’atteinte hépatique." Electronic Thesis or Diss., Sorbonne université, 2024. https://accesdistant.sorbonne-universite.fr/login?url=https://theses-intra.sorbonne-universite.fr/2024SORUS170.pdf.
Full textSarcopenic obesity (SO) is a condition characterized by the coexistence of obesity and sarcopenia, the latter defined as a reduction in muscle mass and function. Diagnosing SO is highly complex due to the lack of universally accepted diagnostic criteria, leading to imprecise diagnoses and highly variable prevalence estimates. Given this scenario, this thesis aimed to develop an empirical diagnostic tool for SO using artificial intelligence, based on the analysis of body composition. We developed the AIM-SO score in a population of patients with overweight/obesity and tested it in two other populations: patients with severe obesity undergoing bariatric surgery (BS) and the general population of the UK Biobank. A longitudinal study with a one-year follow-up was conducted in subjects who underwent BS. We examined clinical correlations, particularly cardiometabolic and hepatic, including perioperative histological findings in the bariatric cohort. The prevalence of SO was similar across these three cohorts. SO diagnosed by the AIM-SO score was associated with multiple cardiometabolic comorbidities and more severe inflammatory and fibrosing liver damage. Despite weight loss, the metabolic benefit (remission of comorbidities) after BS was lower in patients with SO. Preliminary analyses of the UK Biobank cohort showed a significant association between SO diagnosed by the AIM-SO score and parameters of muscular functionality, particularly muscle strength. We propose this new diagnostic tool to standardize the SO diagnosis and identify patients with obesity and sarcopenia who exhibit more severe cardiometabolic and hepatic phenotype. Diagnosing SO could also inform the expected benefit of various weight loss interventions, thus contributing to personalized medical management
Lodder, Jasper. "L’autophagie macrophagique protège contre l'atteinte hépatique et la fibrose au cours de la maladie alcoolique du foie." Thesis, Paris Est, 2014. http://www.theses.fr/2014PEST0067.
Full textAlcohol abuse and non-alcoholic fatty liver disease (NAFLD) are leading causes of liver-related morbi-mortality in Western countries that may lead to accumulation of fibrosis in the liver. Efficient treatments are lacking and there is currently no molecule approved for the treatment of liver fibrosis. Hepatic macrophages play a pivotal role in the initiation and perpetuation of the inflammatory response in fatty liver disease and in progression to fibrosis. Autophagy is a lysosomal degradation pathway that limits the production of pro-inflammatory cytokines. The aim of my thesis was to explore the contribution of macrophage autophagy on alcohol-induced liver injury and fibrosis.In a first study, we show that mice invalidated for the autophagy-gene ATG5 in myeloid cells (Atg5Mye-/- mice) develop exacerbated fibrosis as compared to WT littermates in response the hepatotoxin CCl4. Moreover, Atg5Mye-/- mice produce higher hepatic levels of IL-1α and IL-1β, and show enhanced inflammatory cell recruitment associated with exacerbated liver injury. Hepatic myofibroblasts exposed to the conditioned medium of macrophages from Atg5Mye-/- mice displayed increased profibrogenic gene expression, which could be blunted by neutralizing IL-1α and IL-1β in the conditioned medium of Atg5-/- macrophages. Finally, administration of an IL-1R1 antagonist to Atg5Mye-/- mice exposed to carbon tetrachloride blunted liver injury and fibrosis, revealing that the deleterious effects of macrophage autophagy invalidation are mediated through IL-1α/β.In a second study, we generated mice invalidated for CB2 receptor (CB2Mye−/− mice) in myeloid cells. These mice showed enhanced alcohol-induced pro-inflammatory gene expression and hepatic steatosis as compared to WT littermates. Conversely, mice administered JWH-133 show reduced alcohol-induced liver injury. Activation of the CB2 receptor by JWH-133 increased macrophage autophagy in the livers of alcohol-fed mice, whereas autophagy was inhibited of alcohol-fed CB2Mye−/− mice. In cultured peritoneal macrophages, JWH-133 reduced the induction of inflammatory genes by LPS in WT peritoneal macrophages, but not in ATG5-deficient cells, suggesting that the anti-inflammatory and anti-steatogenic effects of the CB2 receptor are mediated through autophagy. Indeed, the CB2 agonist could protect against alcohol-induced liver inflammation and steatosis in WT, but not in ATG5Mye−/− mice.These results uncover macrophage autophagy as a novel anti-inflammatory pathway that regulates liver fibrosis, and identify CB2 receptor in macrophages as regulator of autophagy that protects from alcohol-induced steatosis by inhibiting hepatic inflammation. Exploiting macrophage autophagy may therefore be an interesting novel target in the treatment of chronic liver disease
Book chapters on the topic "Sévérité de l'atteinte hépatique"
Castéra, Laurent. "12 Évaluation non invasive de la sévérité de la maladie hépatique liée au virus de l’hépatite B." In Hépatite B, 193–210. EDP Sciences, 2020. http://dx.doi.org/10.1051/978-2-84254-223-8-015.
Full textCastéra, Laurent. "12 Évaluation non invasive de la sévérité de la maladie hépatique liée au virus de l’hépatite B." In Hépatite B, 193–210. EDP Sciences, 2020. http://dx.doi.org/10.1051/978-2-84254-223-8.c015.
Full text